Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study

Table 5

Treatment efficacy in subgroups identified on the basis of maximum cell dose per administration.

Maximum dose (×10^6/kg)	N	Average QoL response per one administration; ( chi^2 = not significant)					Developmental breakthrough; ( chi^2 with Yates )						Proportion of patients with developmental breakthrough
		<1				≥4	0	1	2	3	4	5
≤0.87 (≤Q1)	14	5	4	3	1	0	7	4	1	1	1	0	14.3%
0.87-≤1.0 (Q1-Q2)	14	8	3	2	1	0	11	1	1	0	1	0	7.1%
1.0-≤1.17 (Q2-Q3)	14	6	4	2	1	1	9	0	1	1	3	0	28.6%
>1.17 (>Q3)	12	4	3	5	0	0	6	0	0	5	1	0	50%

QoL: quality of life; Q: quartile. The highest improvement in quality of life between two consecutive assessments. Cells marked in bold represent categorization used in Yates’ chi-square test.